ABSTRACT: Glycosaminoglycans (GAGs) play critical roles in diverse processes ranging from viral infection to neuroregeneration. Their regiospecific sulfation patterns, which are generated by sulfotransferases, are key structural determinants that underlie their biological activity. Small-molecule modulators of these sulfotransferases could serve as powerful tools for understanding the physiological functions of GAGs, as well as potential therapeutic leads for human diseases. Here, we report the development of the first cell-permeable, small-molecule inhibitor selective for GAG sulfotransferases, which was obtained using a high-throughput screen targeted against Chst15, the sulfotransferase responsible for biosynthesis of chondroitin sulfate-E (CS-E). We demonstrate that the molecule specifically inhibits GAG sulfotransferases in vitro, decreases CS-E and overall sulfation levels on cell-surface and secreted chondroitin sulfate proteoglycans (CSPGs), and reverses CSPGmediated inhibition of axonal growth. These studies pave the way toward a new set of pharmacological tools for interrogating GAG sulfationdependent processes and may represent a novel therapeutic approach for neuroregeneration.
INTRODUCTION
Glycosaminoglycans (GAGs) play important roles in a myriad of cellular processes, including viral invasion, [1] [2] [3] [4] cancer metastasis, 1, [5] [6] [7] development, 1, 3, 8, 9 and spinal cord injury. 7, [9] [10] [11] [12] Their diverse biological activities are believed to stem from their complex structures, which allow them to interact with a wide range of proteins. 1, 3, 7, 13, 14 GAGs are long, linear polysaccharides that display various patterns of sulfation. For example, chondroitin sulfate (CS) GAGs are assembled from glucuronic acid (GlcA) and N-acetylgalactosamine (GalNAc) disaccharide units that contain at least four distinct sulfation motifs: CS-A, CS-C, CS-D, and CS-E. 7, 12 Numerous studies suggest that specific sulfation motifs can serve as key structural elements for protein recognition and the regulation of downstream signaling. 1, 7, [14] [15] [16] [17] The sulfation patterns of GAGs are controlled by a family of sulfotransferases. [18] [19] [20] [21] Two major classes of the enzymes, the cytosolic and membrane-associated sulfotransferases, catalyze the transfer of a sulfuryl group from the donor 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to a variety of amine-and hydroxylcontaining substrates. 18, 21 The cytosolic sulfotransferases act on small-molecule substrates such as xenobiotics. With only one exception, the sulfotransferases responsible for modifying GAG polysaccharides are type II transmembrane proteins that reside in the Golgi apparatus. All sulfotransferases have a structurally conserved PAPS-binding site, but distinct acceptor binding sites. 18, 21 Although numerous cytosolic sulfotransferases have been crystallized, only limited structural and functional information on GAG sulfotransferases is available, which has hindered efforts to design tools to target these enzymes. Indeed, there are no cell-permeable, smallmolecule inhibitors of any GAG sulfotransferases. Prior work has focused on peptide-or carbohydrate-based inhibitors [22] [23] [24] such as sulfated or iminosugars that displayed limited cell permeability due to the presence of charged groups. 22, 23 Thus, despite long-standing interest in inhibiting GAG sulfotransferases, 25, 26 it was unclear whether small molecules could be developed to selectively target this important class of enzymes in a cellular context. GAG sulfotransferase inhibitors would provide valuable tools for manipulating GAG sulfation patterns and for understanding their roles in biology and disease. The induced expression of specific sulfation motifs is associated with human diseases, including certain cancers, 27, 28 Alzheimer's disease, 29 herpes, 2 and macular corneal dystrophy, 34 but surprisingly, pharmacological tools for manipulating GAG sulfation have been lacking. Cellular sulfation levels can be modulated genetically or by using sodium chlorate, which inhibits PAPS synthetase. 19, 20, [35] [36] [37] However, genetic approaches lack the ease and reversibility of small-molecule inhibitors. Sodium chlorate requires millimolar concentrations and globally affects all sulfotransferases, disrupting the sulfation of hormones, bioamines, xenobiotics, proteins, and other glycans, and inducing off-target effects such as suppression of cell proliferation and replication. [35] [36] [37] [38] Moreover, the toxicity of sodium chlorate due to oxidation of hemoglobin and other metalloproteins limits its biological applications and therapeutic potential. sulfotransferases. As a starting point, we targeted Chst15, the chondroitin sulfotransferase responsible for sulfating the 6-Oposition of N-acetylgalactosamine in CS-A to generate CS-E (Figure 1A) . 19, 20, 40 Previously our laboratory identified the CS-E motif as an important structural determinant in chondroitin sulfate proteoglycans (CSPGs) that inhibits axon regeneration after central nervous system (CNS) injury. 17 Blocking the CS-E motif using a monoclonal antibody specific for CS-E promoted optic nerve regeneration in vivo. 17 As such, Chst15 may represent a novel target for neuronal repair after spinal cord injury, stroke, or other injuries.
In this report, we describe the first cell-permeable, smallmolecule inhibitors of Chst15 and other GAG sulfotransferases. Using a fluorescence-based, high-throughput screen (HTS), we identified two promising scaffolds that upon structure-activity relationship (SAR) optimization led to molecules with improved potency in biochemical and cellular assays. Kinetic analyses revealed a reversible-covalent mechanism of inhibition, along with good selectivity toward GAG sulfotransferases compared to cytosolic sulfotransferases. Notably, the most potent inhibitor decreased CS-E sulfation levels on CSPGs and reversed the inhibitory activity of CSPGs on axonal growth. These studies open the door to a new set of chemical genetic tools for manipulating and understanding GAG-mediated events, as well as a novel potential therapeutic strategy for neuroregeneration.
RESULTS AND DISCUSSION
To discover molecules that inhibit Chst15, we developed a fluorescence-based assay in which Chst15 activity was coupled to the enzyme Sult1c1 ( Figure 1A ). Sult1c1 converts 3'-phosphoadenosine-5'-phosphate (PAP) to PAPS by using 4-methylumbelliferyl sulfate (MUS) as the sulfate donor, resulting in liberation of fluorescent 4-methylumbelliferone (MU). 41, 42 We optimized and validated the assay in 96-well plates to obtain a Zfactor value suitable for high-throughput screening (0.62; Figure  S1 ). The assay was then miniaturized to a 1536-well plate format, and a diversity set of 70,000 compounds was screened at 12.5 μM for its ability to inhibit human Chst15. The hits obtained were counter-screened against Sult1c1, resulting in nineteen compounds (renumbered [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] ) that inhibited Chst15 with little or no Sult1c1 inhibition ( Figure S2A ). To validate these compounds further, we used a direct, sensitive assay that monitored To further evaluate 5, we re-tested its activity and that of several commercially available analogs using the [ 35 S]-labeling assay (Figure S3 ). Although 5 effectively inhibited Chst15, none of the analogs showed improved inhibition, and 5 also unexpectedly showed cross-reactivity toward Sult1c1 when re-evaluated in the counterscreen (12.5 μM, Figure S4 ). We therefore focused our attention on 19. Thirty-one analogs of 19 were synthesized or obtained commercially (Tables 1 and 2 ; Figure S5 ). To facilitate diversification of the molecule, we devised two synthetic routes that allowed for modification of the anilide or vinylbenzene moieties (Scheme 1). Initial formation of the α,β-unsaturated acid followed by an N,N'-diisopropylcarbodiimide (DIC)-promoted amide bond coupling enabled functional groups around the anilide to be altered. Alternatively, synthesis of the cyanoacetamide in two steps permitted incorporation of different vinylbenzene substituents by a piperidinium acetate-catalyzed Knoevenagel condensation. These routes enabled the installation of a wide range of functionalities from a Table 1, Table 2 , and Figure S5 for specific structures. Relative inhibition values were determined from three independent measurements using 25 μM of inhibitor and normalized to the inhibition by compound 19. Figure S5 ) abolished activity, and changing the anilide ring from di-to mono-substitution (25-33) greatly reduced its potency (Table 1 and Figure S5 ). Altering the position of monosubstitution (31, 32) did not change this trend, nor did substitution with larger groups such as tert-butyl (30) , phenyl (33), or fused-phenyl substituents (48, Figure S5 ). The importance of disubstitution was highlighted further upon analysis of various dichloro-substituted analogs (34-36), which had comparable or greater potency than the original compound 19. In particular, compound 34 showed 35% greater potency when compared to 19 in the [ 35 S]-labeling assay. We next explored the importance of the vinylbenzene substituents by synthesizing analogs derived from 34. Removal of any of the three substituents on the vinylbenzene ring (37, 41, 44) greatly attenuated the inhibitory potency of the compound ( Table 2) . Replacement of the bromo substituent with other halogens (38) (39) (40) decreased the activity by up to 2.5-fold, suggesting that the stereoelectronic properties of the bromo group are well suited for binding the enzyme. By comparison, modifications to the methoxy group were more tolerated. For example, replacement of the methoxy with a bromo group (42) led to no significant change in potency, while replacement with an ethoxy group (43) enhanced potency by 26% as compared to 19. However, neither of these analogs exhibited improved potency when compared to 34. Meanwhile, modification of the phenol group to aniline (45) or indazole (49, Figure S5 ) decreased the potency by 3-fold and 26-fold, respectively. Methylation of the phenol functionality also drastically lowered the inhibitory potency for compounds with common scaffolds (e.g. 35 vs. 47, Table 1 and Figure S5 ). Thus, the hydrogen bonding and electronic properties of the phenolic hydroxyl group are important for Chst15 inhibition.
We hypothesized that the α,β-unsaturated cyanoacrylamide moiety might serve as an electrophile for nucleophilic amino acid side chains. Indeed, cyanoacrylamide compounds have been reported to inhibit kinases via a reversible covalent mechanism by reacting with noncatalytic cysteine residues. 43, 44 Rotating frame nuclear Overhauser effect spectroscopy (ROESY) data suggested that the E-isomer is generated in 34 after the Knoevengel condensation ( Figure S6 ). Specifically, correlations between the amide and alkene protons of 34 were detected, which is only possible in the E-configuration. Reduction of this E-olefin using Pd/C abolished the dosedependent effects of 34 (50, Figure S5 ).
To investigate the electrophilic potential of 34, we incubated it with a surrogate nucleophile, β-mercaptoethanol (BME, Figure  S7A ). Consistent with the formation of a covalent thioether adduct, 43 we observed a decrease in the UV-visible absorption band corresponding to the cyanoacrylamide moiety (λmax = 378 nm; Figure S7B ). Upon ten-fold dilution of the sample treated with BME into phosphate buffered saline (PBS), the absorbance was restored as compared to dilution into PBS containing BME, suggesting that formation of the adduct was reversible ( Figure S7C ). Further evidence for a reversible covalent adduct was obtained by 1 H NMR spectroscopy ( Figure S7D ). Incubation of 34 with BME led to partial loss of the olefinic proton ( = 7.83 ppm) and appearance of an aliphatic β-proton ( = 4.49 ppm). Peak integrations indicated that ~57% of the population had formed the thioether adduct, and this population was reduced to ~37% upon two-fold dilution into PBS.
We also examined whether 34 inhibits Chst15 through a reversible covalent mechanism by pre-incubating the inhibitor with Chst15 for various lengths of time. Longer pre-incubation times lead to greater inhibition of the enzyme, consistent with a covalent mechanism of action ( Figure S8A ). However, unlike the inhibition typically observed with irreversible covalent inhibitors, the activity of Chst15 was rapidly restored in ten-fold dilution experiments even at high concentrations of 34 (up to 100 μM). These observations suggest dissociation of the enzyme-inhibitor complex, thus supporting its reversibility ( Figure S8B ).
To study the mechanism further, we performed pseudo firstorder kinetic analyses with compound 34. When the CS-A substrate concentration was varied under pseudo first-order conditions with respect to PAPS, we obtained Ki and Ki' values of 1.43 μM and 2.45 μM, respectively, and observed a shift in both Vmax and Km indicative of a mixed mode of inhibition ( Figure 2A , Table S1 , Figure S10) . However, when the PAPS concentration was varied under pseudo first-order conditions with respect to the CS-A acceptor substrate, we observed a competitive mode of inhibition with a Ki value of 0.77 μM ( Figure 2B , Table S1, Figure S10 ). Taken together, these results suggest that inhibitor 34 competitively interacts with the PAPS binding site and also likely engages part of the acceptor binding site.
Due to its electrophilic mechanism of action, 34 could potentially react with numerous proteins that contain reactive cysteine residues. Cravatt and co-workers have previously identified reactive cysteine-containing proteins using the iodoacetamide-alkyne probe 51 ( Figure S9A ), which alkylates reactive cysteine residues and allows for visualization of the proteins following copper-catalyzed azide-alkyne cycloaddition (CuAAC). 45 Among the most highly reactive proteins were thioredoxin, protein arginine methyltransferase 1 (PRMT1), aldehyde dehydrogenase 1A (ALDH1A), acetyl-CoA acetyltransferase 1 (ACAT1), and glutathione Stransferase omega 1 (GTSO1). We incubated each of these proteins with iodoacetamide probe 51 (25 μM) in the presence or absence of 34 (10 and 25 μM) for 2 h at room temperature, and then reacted them with 5-carboxytetramethylrhodamine-azide (azido-TAMRA). Importantly, no decrease in the labeling of any of the proteins by 51 was observed, as visualized by in-gel fluorescence ( Figure S9B ). These data indicate that compound 34 does not react non-specifically with some of the most reactive cysteine residues in the proteome. As further evidence, we incubated Neu7 astrocytes in the presence or absence of 34 (25 μM) for 24 h, followed by treatment with 51 for 1 h. Again, the labeling of proteins by iodoacetamide probe 51 was unchanged upon treatment with 34 ( Figure S9B) . Together, our studies provide strong evidence that inhibitor 34 is selective for sulfotransferases over the myriad of reactive cysteine-containing proteins in the proteome.
We next investigated the specificity of 34 against a series of cytosolic and GAG sulfotransferases. Importantly, we observed a clear dichotomy in the ability of 34 to inhibit GAG sulfotransferases compared to cytosolic sulfotransferases ( Figure 2C ). While 34 inhibited Chst15 and other closely related GAG sulfotransferases such as the chondroitin 4-O-sulfotransferase Chst11, the chondroitin 2-O-sulfotransferase Ust, and the heparan 3-Osulfotransferase Hs3st1 (IC50 values 2.0-2.5 μM), its activity against the cytosolic sulfotransferases Sult1e1, Sult2b1a, and Sult2b1b, which modify steroidal substrates, was significantly lower (IC50 values 19-42 μM). Moreover, 34 showed no activity against the cytosolic sulfotransferase Sult1c1 used in the enzyme-coupled assay at the concentrations tested (3-100 μM). Inhibition of other GAG sulfotransferases by 34 is consistent with the high sequence homology (25-81%) shared by GAG sulfotransferases 40, 46, 47 and our observations that 34 engages the PAPS binding pocket. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 58 59 The ability to inhibit GAG sulfation after CNS injury could have important implications for neural regeneration. After CNS injury, reactive astrocytes enter the site of injury and secrete CSPGs as a means to prevent further damage. [9] [10] [11] Previous studies in our laboratory have established that the CS-E sulfation motif is upregulated on these CSPGs and inhibits the growth of sensory axons. 17 Thus, we first examined whether 34 could modulate CS-E expression levels on CSPG-secreting Neu7 astrocytes. 48 Indeed, astrocytes treated with 10 μM or 25 μM of 34 showed a significant, dosedependent decrease in cell-surface CS-E expression, as indicated by immunostaining with a CS-E-specific antibody 49 ( Figure 3A and 3B). Notably, no cytotoxicity was observable at the concentrations tested when analyzed by the trypan blue exclusion assay (up to 25 μM). By comparison, sodium chlorate did not reduce CS-E levels to as large an extent, even at doses as high as 25 mM. Similar results were obtained using NIH3T3 fibroblasts, where significant loss of CS-E expression was observed upon treatment with 34, and 34 had superior potency compared to sodium chlorate ( Figure S11 ).
To characterize the effects of 34 on secreted CSPGs, we purified the CSPGs from Neu7-conditioned media, digested them with chondroitinase ABC (ChABC), and analyzed their disaccharide composition by reverse-phase ion-pair high-performance liquid chromatography (RPIP-HPLC). CSPGs secreted from Neu7 astrocytes treated with 25 μM of 34 displayed a 62.9 ± 17.0% increase in unsulfated chondroitin (uCS) content compared to CSPGs secreted from untreated astrocytes, indicating a decrease in overall sulfation ( Figure 3C , Table S2 ). This overall decrease was accompanied by a specific 67.8 ± 10.9% reduction in the CS-E sulfation motif on secreted CSPGs. Although other CS sulfation motifs were also affected, the CS-E motif was reduced to the largest extent ( Figure S12 ). By comparison, CSPGs secreted from sodiumchlorate-treated cells also displayed lower sulfation compared to untreated cells, albeit to a lesser degree and only in the presence of high concentrations of sodium chlorate (39.7 ± 15.6% increase in uCS; 31.6 ± 10.9 % decrease in CS-E).
Having shown that 34 can effectively inhibit CS-E sulfation levels on both surface-expressed and secreted CSPGs, we next examined whether this mode of inhibition could be exploited to stimu late axonal growth. Sensory dorsal root ganglion neurons (DRGs) adjacent to the rat spinal cord were grown on a substratum coated with the CSPGs secreted from Neu7 astrocytes treated with or without 34. The effects of the CSPGs on neurite outgrowth were determined by immunostaining for the neuronal-specific marker, βIII-tubulin, and quantifying the average neurite length. To our delight, we observed a significant, dose-dependent promotion of neurite outgrowth (30.7 ± 2.5% at 25 μM of 34) when DRGs were grown on CSPGs secreted from treated astrocytes compared to untreated astrocytes ( Figure 4A ). The observed effects could stem from direct inhibition of Chst15 and/or indirect effects on other GAG sulfotransferases such as Chst11, which creates the substrate for Chst15. These results highlight not only the ability of 34 to block known functions of CSPGs but also the potential value of pan-specific GAG sulfotransferase inhibitors. In many cases, the relative contributions of various sulfation motifs and GAG subclasses have not been fully investigated; thus, pan-specific inhibitors may be ideal and enable validation of therapeutic hypotheses.
CNS injury induces tissue damage and leads to formation of a glial scar, which consists predominantly of reactive astrocytes and CSPGs. [9] [10] [11] The glial scar serves as a major barrier to axon regeneration. We used an in vitro boundary assay to simulate the glial scar and assess the ability of 34 to reverse the inhibitory activity of CSPGs. In this assay, purified CSPGs from Neu7 astrocytes treated with or without 34 were mixed with Texas Red dye and spotted onto glass coverslips. DRG neurons were plated onto the coverslips, and the percentage of neurites that crossed the CSPG boundary was quantified. Whereas DRG neurites were strongly repelled by CSPGs from untreated astrocytes, they crossed more freely into boundaries of CSPGs from astrocytes treated with 34 ( Figure 4B ). Thus, compound 34 rendered CSPGs more permissive to axonal growth, demonstrating its ability to modulate sulfation-dependent cellular processes.
Finally, we evaluated the potential to use inhibitor 34 in vivo by profiling its absorption, distribution, metabolism, and elimination (ADME) properties. 34 showed good stability in human, mouse and rat liver microsomes based on intrinsic clearance (Table S3 ).
The in vivo pharmacokinetic (PK) properties of 34 were also evaluated directly in rats. After intravenous injection of compound 34 at a dose of 3.0 mg/kg, the compound had a moderate clearance of 21 mL/min/kg, moderate volume of distribution of 0.97 L/kg, and short terminal half-life of 1.6 h (Table S4 ). These data suggest that direct application of the compound, as opposed to intravenous injection, may be more efficacious for future use in vivo. Taken together, our studies demonstrate that the sulfotransferase inhibitor 34 can diminish the inhibitory effects of CSPGs, and they highlight its promise to be used for the stimulation of neuronal repair.
CONCLUSION
GAG sulfotransferase inhibitors have the potential to be powerful pharmacological tools for elucidating the diverse physiological functions of GAGs and serve as potential therapeutic leads for spinal cord regeneration and human diseases. We report here the discovery of the first cell-permeable, small-molecule inhibitor selective for GAG sulfotransferases. Inhibitor 34 was derived from a highthroughput screen targeted against the CS-E sulfotransferase Chst15 and potently inhibited the sulfation of surface-expressed and secreted CSPGs. Importantly, by decreasing sulfation levels on CSPGs, compound 34 reversed the growth inhibitory effects of CSPGs on sensory axons. These studies demonstrate, for the first time, the ability to modulate a class of enzymes for which, despite high interest, no cell-permeable, small-molecule inhibitors exist. Furthermore, they highlight the promise of using a sulfotransferase inhibitor-based strategy, and potentially 34 or its derivatives, for the stimulation of neuronal growth after injury, stroke, or neurodegenerative disease. Finally, compound 34 provides a lead scaffold that may be further developed to target individual sulfotransferases with high specificity. Owing to the major lack of tools for studying sulfation, we envision that chemically-tuned small molecules capable of modulating specific GAG sulfation patterns will find extensive use as tools in manipulating and understanding GAGdependent physiological and pathological processes.
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